SecurityAWH / Allied World Assurance Company Holding AG (H01531104)
CEO, Allied World Re Mgt CoBender John
IndustryFire, Marine, and Casualty Insurance
Institutional Owners16
Institutional Shares5,557,764 - 6.35%
Common Shares Outstanding87,484,665 shares (as of 2017-03-31)
Institutional Value$ 826,025,000 USD
Related 01959EAB4 / Allied World 5.50% Senior Notes 11/15/20
01959EAA6 / Allied World Assurance 7.5% Due 8/1/16

Institutional Stock Ownership and Shareholders()

AWH / Allied World Assurance Company Holding AG Institutional Ownership

Allied World Assurance Company Holding AG (NYSE:AWH) has 16 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,557,764 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., Perkins Investment Management, LLC, BlackRock Fund Advisors, Alpine Group Usvi, Llc, BlackRock Advisors LLC, Keeley Asset Management Corp, BlackRock Group LTD, EverPoint Asset Management, LLC, Janus Capital Management Llc, and BlackRock Investment Management, LLC.
Allied World Assurance Company Holding AG (NYSE:AWH) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/awh"><img src="https://images.fintel.io/us-awh-so.png" alt="AWH / Allied World Assurance Company Holding AG Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-14 13F-HR KEELEY ASSET MANAGEMENT CORP 252,458 238,778 -5.42 10,204 12,825 25.69
2017-02-10 13F-HR BlackRock Advisors LLC 355,995 279,702 -21.43 14,389 15,023 4.41
2017-02-10 13F-HR BlackRock Group LTD 179,388 154,642 -13.79 7,250 8,306 14.57
2017-08-10 13F-HR Century Capital Management, LLC 49,604 0 -100.00 2,634 0 -100.00
2017-08-11 13F-HR BancorpSouth Inc 4,965 4,965 0.00 264 263 -0.38
2017-10-26 13F-HR Acrospire Investment Management LLC 200 0 -100.00 11 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 56,037 50,359 -10.13 2,265 2,705 19.43
2017-02-14 13F-HR EverPoint Asset Management, LLC 77,778 100,000 28.57 3,144 5,371 70.83
2017-07-24 13F-HR Breton Hill Capital Ltd. 20,866 0 -100.00 1,108 0 -100.00
2017-01-24 13F-HR SPHINX TRADING, LP 2,000 107
2017-02-09 13F-HR J.Safra Asset Management Corp 2,845 0 -100.00 115 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 2,400,943 2,271,158 -5.41 97,046 121,984 25.70
2017-05-11 13F-HR EDGE ASSET MANAGEMENT, INC 432,127 0 -100.00 23,210 0 -100.00
2017-05-15 13F-HR Perkins Investment Management, LLC 1,608,846 1,050,137 -34.73 86,411 55,762 -35.47
2017-02-10 13F-HR BlackRock Japan Co. Ltd 1,037 0 -100.00 42 0 -100.00
2017-08-14 13F-HR Cantab Capital Partners LLP 26,689 9,996 -62.55 1,417,000 529,000 -62.67
2017-08-08 13F-HR Airain ltd 284,814 20,000 -92.98 15,124 1,058 -93.00
2017-08-14 13F-HR Alpine Group Usvi, Llc 299,241 15,830
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 32,300 71,200 120.43 1,735 3,781 117.93
2017-01-13 13F-HR MetLife Securities, Inc 1,140 61
2017-01-23 13F-HR KANALY TRUST CO 238 238 0.00 10 13 30.00
2017-02-10 13F-HR BlackRock Fund Advisors 940,152 1,004,208 6.81 38,001 53,936 41.93

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: H01531104